Karin Kur, Erofili Papadopoulou, Meital Nidam, Michal Fertouk, Omer Binyamini, Silvina Friedlander Barenboim, Towy Sorel Lazarovitci, Liran Domachevsky, Noam Yarom
{"title":"PSMA PET-CT 在鉴别药物性颌骨骨坏死和颌骨转移方面的诊断价值。","authors":"Karin Kur, Erofili Papadopoulou, Meital Nidam, Michal Fertouk, Omer Binyamini, Silvina Friedlander Barenboim, Towy Sorel Lazarovitci, Liran Domachevsky, Noam Yarom","doi":"10.1093/dmfr/twae034","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Medication-related osteonecrosis of the jaw (MRONJ) and jaw metastasis might share similar clinical and radiographic characteristics, with both demonstrating F-18 fluorodeoxyglucose (FDG) uptake on PET-CT. Prostate-specific membrane antigen (PSMA) PET-CT is used to demonstrate prostate cancer dissemination. Unlike FDG PET-CT, PSMA PET-CT is more specific to cancer than to inflammation. Therefore, we hypothesized that it might be a useful tool to differentiate between MRONJ and jaw metastasis.</p><p><strong>Methods: </strong>All files of prostate cancer patients diagnosed with MRONJ and with available PSMA PET-CT studies were retrieved. A similar number of solid cancer patients with MRONJ and with available FDG PET-CT studies served as a second study group. All studies were reviewed by 2 blinded co-investigators (L.D. and M.F.).</p><p><strong>Results: </strong>Seventeen patients who underwent PSMA PET-CT (24 studies) and 15 patients who underwent FDG PET-CT (29 studies) met the inclusion criteria. All patients with FDG PET-CT studies showed pathological uptake at the site of MRONJ in at least one of their studies versus only 23.5% of patients in the PSMA PET-CT group (P < .001). FDG PET-CT studies showed pathological uptake in 89.6% of the studies compared with only 20.8% in the PSMA PET-CT group (P < .001). The mean standardized uptake value (SUVmax) and the mean uptake volume in the FDG PET-CT group were significantly higher compared with the PSMA PET-CT group (P < .001 and P < .005, respectively). The interclass correlation coefficient for all parameters was higher than 0.95.</p><p><strong>Conclusions: </strong>PSMA PET-CT is useful to differentiate between MRONJ and jaw metastasis.</p>","PeriodicalId":11261,"journal":{"name":"Dento maxillo facial radiology","volume":" ","pages":"497-500"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The diagnostic value of prostate-specific membrane antigen PET-CT in differentiating medication-related osteonecrosis of the jaw and metastasis to the jawbone.\",\"authors\":\"Karin Kur, Erofili Papadopoulou, Meital Nidam, Michal Fertouk, Omer Binyamini, Silvina Friedlander Barenboim, Towy Sorel Lazarovitci, Liran Domachevsky, Noam Yarom\",\"doi\":\"10.1093/dmfr/twae034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Medication-related osteonecrosis of the jaw (MRONJ) and jaw metastasis might share similar clinical and radiographic characteristics, with both demonstrating F-18 fluorodeoxyglucose (FDG) uptake on PET-CT. Prostate-specific membrane antigen (PSMA) PET-CT is used to demonstrate prostate cancer dissemination. Unlike FDG PET-CT, PSMA PET-CT is more specific to cancer than to inflammation. Therefore, we hypothesized that it might be a useful tool to differentiate between MRONJ and jaw metastasis.</p><p><strong>Methods: </strong>All files of prostate cancer patients diagnosed with MRONJ and with available PSMA PET-CT studies were retrieved. A similar number of solid cancer patients with MRONJ and with available FDG PET-CT studies served as a second study group. All studies were reviewed by 2 blinded co-investigators (L.D. and M.F.).</p><p><strong>Results: </strong>Seventeen patients who underwent PSMA PET-CT (24 studies) and 15 patients who underwent FDG PET-CT (29 studies) met the inclusion criteria. All patients with FDG PET-CT studies showed pathological uptake at the site of MRONJ in at least one of their studies versus only 23.5% of patients in the PSMA PET-CT group (P < .001). FDG PET-CT studies showed pathological uptake in 89.6% of the studies compared with only 20.8% in the PSMA PET-CT group (P < .001). The mean standardized uptake value (SUVmax) and the mean uptake volume in the FDG PET-CT group were significantly higher compared with the PSMA PET-CT group (P < .001 and P < .005, respectively). The interclass correlation coefficient for all parameters was higher than 0.95.</p><p><strong>Conclusions: </strong>PSMA PET-CT is useful to differentiate between MRONJ and jaw metastasis.</p>\",\"PeriodicalId\":11261,\"journal\":{\"name\":\"Dento maxillo facial radiology\",\"volume\":\" \",\"pages\":\"497-500\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dento maxillo facial radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/dmfr/twae034\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dento maxillo facial radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/dmfr/twae034","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
The diagnostic value of prostate-specific membrane antigen PET-CT in differentiating medication-related osteonecrosis of the jaw and metastasis to the jawbone.
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) and jaw metastasis might share similar clinical and radiographic characteristics, with both demonstrating F-18 fluorodeoxyglucose (FDG) uptake on PET-CT. Prostate-specific membrane antigen (PSMA) PET-CT is used to demonstrate prostate cancer dissemination. Unlike FDG PET-CT, PSMA PET-CT is more specific to cancer than to inflammation. Therefore, we hypothesized that it might be a useful tool to differentiate between MRONJ and jaw metastasis.
Methods: All files of prostate cancer patients diagnosed with MRONJ and with available PSMA PET-CT studies were retrieved. A similar number of solid cancer patients with MRONJ and with available FDG PET-CT studies served as a second study group. All studies were reviewed by 2 blinded co-investigators (L.D. and M.F.).
Results: Seventeen patients who underwent PSMA PET-CT (24 studies) and 15 patients who underwent FDG PET-CT (29 studies) met the inclusion criteria. All patients with FDG PET-CT studies showed pathological uptake at the site of MRONJ in at least one of their studies versus only 23.5% of patients in the PSMA PET-CT group (P < .001). FDG PET-CT studies showed pathological uptake in 89.6% of the studies compared with only 20.8% in the PSMA PET-CT group (P < .001). The mean standardized uptake value (SUVmax) and the mean uptake volume in the FDG PET-CT group were significantly higher compared with the PSMA PET-CT group (P < .001 and P < .005, respectively). The interclass correlation coefficient for all parameters was higher than 0.95.
Conclusions: PSMA PET-CT is useful to differentiate between MRONJ and jaw metastasis.
期刊介绍：
Dentomaxillofacial Radiology (DMFR) is the journal of the International Association of Dentomaxillofacial Radiology (IADMFR) and covers the closely related fields of oral radiology and head and neck imaging.
Established in 1972, DMFR is a key resource keeping dentists, radiologists and clinicians and scientists with an interest in Head and Neck imaging abreast of important research and developments in oral and maxillofacial radiology.
The DMFR editorial board features a panel of international experts including Editor-in-Chief Professor Ralf Schulze. Our editorial board provide their expertise and guidance in shaping the content and direction of the journal.
Quick Facts:
- 2015 Impact Factor - 1.919
- Receipt to first decision - average of 3 weeks
- Acceptance to online publication - average of 3 weeks
- Open access option
- ISSN: 0250-832X
- eISSN: 1476-542X
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
